Exelixis Inc.

(EXEL) Trade

By |

Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

Contact Information

Website: www.exelixis.com
Email: shubbard@exelixis.com
Main Phone: +1 650 837-7000
Address: 1851 Harbor Bay Parkway
State: CA
City / Town: Alameda
Country: USA
Postal Code: 94502

Issuer Information

Exchange: NGS
CEO: Michael M. Morrissey
Employees: 617
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

View More

Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

Contact Information

Website: www.exelixis.com
Email: shubbard@exelixis.com
Main Phone: +1 650 837-7000
Address: 1851 Harbor Bay Parkway
State: CA
City / Town: Alameda
Country: USA
Postal Code: 94502

Issuer Information

Exchange: NGS
CEO: Michael M. Morrissey
Employees: 617
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

View More
$ 16.56 $ 0.10 (0.61%)
Last Price 16.56 Change $ 0.10 Change % 0.61 Tick N/A
Bid 16.56 Bid Size 200.00 Ask 16.57 Ask Size 300.00
Open 16.28 High 16.68 Low 15.95 Prev Close 16.46
Last Trade Volume 868,716 52 Wk Hi 25.21 52 Wk Low 13.67
Market Cap 5.1 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 305,393,240.00 EPS (TTM) 1.02 PE Ratio 16.90 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 35 97
Number of Buys 21 48
Number of Sells 14 49
Net Activity 67225 16693
Last 10 Buys Shares
Lance Willsey 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Vincent T. Marchesi 1,000
Vincent T. Marchesi 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Lance Willsey 1,000
Vincent T. Marchesi 1,000
Last 10 Sell Shares
Michael M. Morrissey 1,000
Lance Willsey 1,000
Patrick J. Haley 1,000
Vincent T. Marchesi 1,000
Charles Cohen 1,000
Patrick J. Haley 1,000
Stelios Papadopoulos 1,000
Patrick J. Haley 1,000
Jeffrey J. Hessekiel 1,000
Gisela M. Schwab 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 40 40 40 40
Low Target Price Estimate 29 29 29 29
Mean Target Price Estimate 33.83 33.83 33.83 33.83
Standard Deviation 5.12 5.12 5.12 5.12
Date of Most Recent Estimate 06/01/18 05/29/18 05/17/18 06/01/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 5 5 5 5
Moderate Buy 2 2 1 2
Hold 1 1 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.5 1.5 1.63 1.8